Novo Nordisk A/S FY2025 sales rise 6 percent to DKK 309.1 billion

Reuters02-04

<a href="https://laohu8.com/S/NVO">Novo Nordisk</a> A/S FY2025 sales rise 6 percent to DKK 309.1 billion

Novo Nordisk A/S reported full-year 2025 sales of DKK 309.10 billion, representing a 6 percent increase. Operating profit for the period was DKK 127.70 billion, down 1 percent, primarily impacted by around DKK 8 billion in costs related to a company-wide transformation. Excluding these costs, operating profit would have increased by 6 percent. The company reached nearly 46 million people with its innovative treatments during 2025, despite a challenging year. Novo Nordisk highlighted encouraging early uptake from the US launch of the Wegovy pill and reiterated confidence in its ability to drive volume growth in the coming years. Looking ahead to 2026, the company expects pricing headwinds in an increasingly competitive market and anticipates regulatory decisions for new treatments, including Mim8 for haemophilia and CagriSema for obesity, alongside several key research and development read-outs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001162815-en) on February 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608805580?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 00:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608805580","market":"fut","top_or_hot":-1,"title":"Novo Nordisk A/S FY2025 sales rise 6 percent to DKK 309.1 billion","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> A/S FY2025 sales rise 6 percent to DKK 309.1 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Novo Nordisk A/S reported full-year 2025 sales of DKK 309.10 billion, representing a 6 percent increase. Operating profit for the period was DKK 127.70 billion, down 1 percent, primarily impacted by around DKK 8 billion in costs related to a company-wide transformation. Excluding these costs, operating profit would have increased by 6 percent. The company reached nearly 46 million people with its innovative treatments during 2025, despite a challenging year. Novo Nordisk highlighted encouraging early uptake from the US launch of the Wegovy pill and reiterated confidence in its ability to drive volume growth in the coming years. Looking ahead to 2026, the company expects pricing headwinds in an increasingly competitive market and anticipates regulatory decisions for new treatments, including Mim8 for haemophilia and CagriSema for obesity, alongside several key research and development read-outs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001162815-en) on February 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk A/S FY2025 sales rise 6 percent to DKK 309.1 billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk A/S FY2025 sales rise 6 percent to DKK 309.1 billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-04 00:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> A/S FY2025 sales rise 6 percent to DKK 309.1 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Novo Nordisk A/S reported full-year 2025 sales of DKK 309.10 billion, representing a 6 percent increase. Operating profit for the period was DKK 127.70 billion, down 1 percent, primarily impacted by around DKK 8 billion in costs related to a company-wide transformation. Excluding these costs, operating profit would have increased by 6 percent. The company reached nearly 46 million people with its innovative treatments during 2025, despite a challenging year. Novo Nordisk highlighted encouraging early uptake from the US launch of the Wegovy pill and reiterated confidence in its ability to drive volume growth in the coming years. Looking ahead to 2026, the company expects pricing headwinds in an increasingly competitive market and anticipates regulatory decisions for new treatments, including Mim8 for haemophilia and CagriSema for obesity, alongside several key research and development read-outs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001162815-en) on February 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2095319765.USD","symbol_name":"Natixis Thematics Subscription Economy R/A USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL784bJ7:1","article_id":"2608805580","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608805580","pubTimestamp":1770136725,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Novo Nordisk A/S reported full-year 2025 sales of DKK 309.10 billion, representing a 6 percent increase. Operating profit for the period was DKK 127.70 billion, down 1 percent, primarily impacted by around DKK 8 billion in costs related to a company-wide transformation. Excluding these costs, operating profit would have increased by 6 percent. The company reached nearly 46 million people with its innovative treatments during 2025, despite a challenging year. Novo Nordisk highlighted encouraging early uptake from the US launch of the Wegovy pill and reiterated confidence in its ability to drive volume growth in the coming years. Looking ahead to 2026, the company expects pricing headwinds in an increasingly competitive market and anticipates regulatory decisions for new treatments, including Mim8 for haemophilia and CagriSema for obesity, alongside several key research and development read-outs.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC"},"translate_title":"诺和诺德公司2025财年销售额增长6%至3,091亿丹麦克朗","themeId":"bcb73b9a2718796b6bdfcc143da1014d","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9},"content_text":"Novo Nordisk A/S FY2025 sales rise 6 percent to DKK 309.1 billion\n    \n\n        Novo Nordisk A/S reported full-year 2025 sales of DKK 309.10 billion, representing a 6 percent increase. Operating profit for the period was DKK 127.70 billion, down 1 percent, primarily impacted by around DKK 8 billion in costs related to a company-wide transformation. Excluding these costs, operating profit would have increased by 6 percent. The company reached nearly 46 million people with its innovative treatments during 2025, despite a challenging year. Novo Nordisk highlighted encouraging early uptake from the US launch of the Wegovy pill and reiterated confidence in its ability to drive volume growth in the coming years. Looking ahead to 2026, the company expects pricing headwinds in an increasingly competitive market and anticipates regulatory decisions for new treatments, including Mim8 for haemophilia and CagriSema for obesity, alongside several key research and development read-outs.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001162815-en) on February 03, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608805580","isCrawlerRequest":true}